Cytotoxic Antibody Drug Conjugates (CADCs)
Goodwin Biotechnology-- Your Single Source Solution™ for Cytotoxic ADCs
Goodwin Biotechnology has the experience, expertise, and capability to develop and manufacture highly potent CADCs from proof of concept through to non-clinical and clinical use, late stage as well as commercial manufacturing.
We have expanded our Bioconjugation capabilities by adding a dedicated suite for developing and manufacturing cytotoxic ADCs up to Safebridge level 4/5!
To learn more, please click the following:
Why Goodwin Biotechnology?
Goodwin Biotechnology will Design and Execute your Process Development and Manufacturing Strategy
Goodwin Biotechnology will Design and Execute your Formulation and Fill & Finish Strategy
Goodwin Biotechnology will Design and Execute an Approach for Characterization of your Cytotoxic Antibody Drug Conjugate
Goodwin Biotechnology will help Design your Regulatory Strategy
For more information on our Cytotoxic Antibody Drug Conjugate (CADCs) services please fill out the form below.
Blending Science With Art
The successful development of effective CADCs combines elements of science with the vision of an artist tweaking and optimizing the antibody-linker-drug pairing, particularly since covalent cross linking of the antibody onto a linker is essential for proper drug delivery to the intended target cells. Many CADCs are constructed through the reaction of drugs or chemicals cross linking reagents with appropriate solvent-accessible, reactive amino acids (e.g., lysine and cysteine) on the antibody. The linkers generally fall into one of two categories:
Cleavable Linkers – after the antibody/linker/drug complex enters the target cell and, following internalization, the resulting linker-drug complex is the active drug.
For more information on our unique non-cleavable SteadFast™ or cleavable FlexRelease™ Linker Technologies, please fill out the form above.
Advancing the Art of Cytotoxic Antibody Drug Conjugates (CADCs) through Science
The advent of highly potent Cytotoxic Antibody Drug Conjugates (CADCs) holds the promise of introducing breakthrough treatments for a number of diseases because they have the ability to specifically target the diseased cell and deliver a potent payload to selectively kill the diseased cells. This fulfills the promise of dramatically increasing efficacy and decreasing toxicity when compared to conventional, systemic treatment approaches.
The complexity associated with the covalent linking of an antibody to a cytotoxic agent has become a core development focus of companies developing proprietary CADC platforms, and the innovators are focusing on four elements essential to developing an effective CADC: